The product information for every mesalazine medicine in the UK now includes a warning about a very rare side effect called idiopathic intracranial hypertension (IIH). The Medicines and Healthcare products Regulatory Agency (MHRA), which regulates medicines in the UK, announced the change in December 2025. It says the benefits of mesalazine still outweigh its risks, and the medicine has not been restricted in any way.
Mesalazine is one of the most widely used treatments for ulcerative colitis (UC) and is also used in Crohn's disease. The warning covers every form: tablets, granules, suppositories, enemas and rectal foam.
What is IIH?
IIH is a rise in the pressure of the fluid around the brain, inside the skull. "Idiopathic" means the cause is not known, "intracranial" means inside the skull and "hypertension" means raised pressure.
IIH is not normally life-threatening. In rare cases, however, it can cause serious problems with eyesight, which is why it needs to be spotted and treated early.
How rare is it?
Very rare. A European review of safety data on mesalazine found a link with IIH based on a very small number of reports, and the UK's Commission on Human Medicines, which advises the government on medicines, agreed that patients and doctors should be told.
In the UK, the MHRA has received 6 reports of raised pressure in the skull in people taking mesalazine through its Yellow Card scheme, which collects suspected side effects. A report does not prove that the medicine caused the problem. For comparison, around 1.5 million prescription items for mesalazine are issued each year in England alone, and IIH also occurs in people who don't take mesalazine: between 1.8 and 7.8 people in every 100,000 develop it each year in Scotland, England and Wales.
Symptoms to look out for
Tell your doctor straight away if you take mesalazine and notice:
- A headache that keeps coming back and gets progressively worse
- Problems with your eyesight
- Ringing or buzzing in your ears
- Back pain or neck pain
- Dizziness
None of these symptoms on its own means you have IIH, and most have much more common causes. But a worsening, recurring headache, or any change in your vision, should always be checked.
What it means for you
For almost everyone taking mesalazine, nothing changes. Your doctor should now mention IIH when they first prescribe it, and take extra care if you have had IIH, or been thought to have it, in the past. If that applies to you, make sure your IBD team or GP knows.
If IIH does develop, the MHRA advises doctors to consider stopping mesalazine and to start treatment for IIH straight away, involving specialists in neurology and eye care where needed. That decision would be made with you, and your IBD team would talk to you about other ways of keeping your colitis under control.
Please don't stop mesalazine because of this warning without talking to your IBD team first. Stopping can make a flare-up more likely, and for most people the benefits are much greater than this very small risk. You can report any suspected side effect through the MHRA's Yellow Card scheme, and your pharmacist can help.
For more about the medicine, including its other side effects, see Mesalazine, and if your symptoms return, see What to Do in a Flare-Up.
Ref: Medicines and Healthcare products Regulatory Agency. Mesalazine and idiopathic intracranial hypertension. Drug Safety Update, volume 19, issue 5, December 2025.